Geert Nygaard has joined Glycorex Transplantation AB (publ.) as Chief Executive Officer
As previously announced, Geert Nygaard has joined Glycorex Transplantation AB (publ.) as its CEO as per 15th December 2021.
Geert brings over 30 years of experience in the diagnostics and life science markets from a variety of senior leadership roles with Abbott Laboratories, TECAN, Epigenomics and DAKO.
“I am very excited to join the Glycorex Transplantation team as we are entering the next phase of expansion”, said Geert Nygaard. “We are focusing on increasing the global market reach for our existing Glycosorb ABO product and launching new exciting products for Universal Blood Plasma and Rheumatoid Arthritis.”
Contact
Geert Nygaard, CEO, Glycorex Transplantation AB.
E-mail: info@glycorex.se, phone: 046-286 52 30
Brief information about the company
Glycosorb® ABO is one of Glycorex Transplantation AB's self-developed proprietary medical devices that is used clinically in four continents to facilitate blood group-compatible transplants, especially in kidney transplants from related living donors, but the product is also used in liver, heart, lung and stem cell transplantation. The product has so far been used in more than 5,000 kidney transplants. The short-term and long-term results are excellent. The results have been presented in over 60 scientific articles in reputable medical journals. Each kidney transplant has been estimated to save up to SEK 5 million in dialysis costs alone. Each kidney transplant saves about 150 dialysis treatments per year, meaning that the over 5,000 kidney transplants performed after Glycosorb® treatments, can be estimated to save over 700,000 dialysis treatments per year. In addition to Europe, the product is used in India, Canada, Israel, Singapore, Thailand, Mexico and Australia, for example.The company has also developed a CE-marked medical device for the development of universal blood plasma and are developing products for the specific reduction of autoantibodies in the treatment of autoimmune diseases, as well as products for specific reduction of galectins. The company also develops products for the simultaneous reduction of blood group A/B specific antibodies and HLA antibodies (tissue-specific antibodies). The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis. There are approximately 5 million patients in the EU who have this disease.
Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.